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Abstract
The newly discovered Merkel Cell Polyomavirus (MCPyV) resides in approximately 80% of Merkel cell carcinomas (MCC).
Causal role of MCPyV for this rare and aggressive skin cancer is suggested by monoclonal integration and truncation of large
T (LT) viral antigen in MCC cells. The mutated MCPyV has recently been found in highly purified leukemic cells from patients
with chronic lymphocytic leukemia (CLL), suggesting a pathogenic role also in CLL. About 50–80% of adults display MCPyV-
specific antibodies. The humoral immunity does not protect against the development of MCC, as neutralizing MCPyV
antibodies occur in higher levels among MCC patients than healthy controls. Impaired T-cell immunity has been linked with
aggressive MCC behavior. Therefore, cellular immunity appears to be important in MCPyV infection surveillance. In order to
elucidate the role of MCPyV-specific Th-cell immunity, peripheral blood mononuclear cells (PBMC) of healthy adults were
stimulated with MCPyV VP1 virus-like particles (VLPs), using human bocavirus (HBoV) VLPs and Candida albicans antigen as
positive controls. Proliferation, IFN-c, IL-13 and IL-10 responses were examined in 15 MCPyV-seropositive and 15
seronegative volunteers. With the MCPyV antigen, significantly stronger Th-cell responses were found in MCPyV-
seropositive than MCPyV-seronegative subjects, whereas with the control antigens, the responses were statistically similar.
The most readily detectable cytokine was IFN-c. The MCPyV antigen tended to induce stronger IFN-c responses than HBoV
VLP antigen. Taken together, MCPyV-specific Th-cells elicit vigorous IFN-c responses. IFN-c being a cytokine with major
antiviral and tumor suppressing functions, Th-cells are suggested to be important mediators of MCPyV-specific immune
surveillance.
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Introduction
Merkel cell polyomavirus (MCPyV) discovered by Feng et al in
2008, is responsible for a rare, yet aggressive neuroendrocrine
neoplasia, Merkel cell carcinoma (MCC) [1,2,3]. The virus has
been shown to be present in 24–89% of MCCs in populations of
varied geographic origins [4–7]. It has been shown to be
integrated clonally into the MCC genome [1,8]. Antibodies
recognizing MCPyV tumor associated antigens appear to be a
relatively specific MCC marker [9]. Recently, an association of
MCPyV infection with chronic lymphocytic leukemia (CLL) was
reported [10–12], yet the causal association remains to be proven.
Serological studies have shown that 50–80% of adults display
MCPyV-specific antibodies [13–15]. Very recently, the presence
of MCPyV DNA sequences was reported in buffy coats of healthy
blood donors pointing to latency/persistence in peripheral blood
leukocytes [16,17]. As MCPyV VLPs can elicit antibody
responses, they have been suggested to be potential vaccine
candidates [18]. However, as neutralizing MCPyV antibodies
occour in high titers among patients, they apparently fail to
prevent MCC tumorigenesis [18]. It is therefore possible that cell
mediated immunity (CMI) may be involved in protection against
MCPyV- induced malignancy. Our aim was to elucidate the
strength and polarization of MCPyV-specific T-helper cell
immunity among asymptomatic adults. T-helper cell mediated
proliferation, interferon-gamma (IFN-c), interleukin-10 (IL-10)
and interleukin-13 (IL-13) responses were studied.
IFN-c is a major antiviral cytokine, produced not only by Th1
cells but also by cytotoxic T-cells and NK cells [19]. It is a critical
extrinsic tumor-suppressor factor in immunocompetent hosts and
it has several types of antitumor actions [20–24]. IL-10 is an
important anti-inflammatory cytokine [25] and its major sources
are T-helper type 2 (Th2) cells and a subset of regulatory T-cells
[26]. IL-10 inhibits Th1 cells, NK cells and macrophages. These
three cell types are required for optimal pathogen clearance, and
they also contribute to tissue damage during infection. In
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consequence, IL-10 can both impede pathogen clearance and
ameliorate immunopathology [25]. The role of this cytokine on
the immune response against cancer is controversial. As it can
inhibit several key phenomena of adaptive immune responses, it
has been considered to allow malignant cells to escape from
immune surveillance [27,28]. By contrast, there is data to suggest
that IL-10 might also favour immune-mediated cancer rejection
[29–32]. IL-13 is an important cytokine produced mainly by Th2
cells [33,34]. It possesses several unique effector functions
including regulation of gastrointestinal parasite expulsion, intra-
cellular parasitism, airway hyperresponsiveness, allergic inflam-
mation [35] and class switch to IgE and IgG4 [36]. The role of IL-
13 in regulating tumor growth depends on the tumor cell type. In
some models inhibition of IL-13 or IL-13 receptors has promoted
tumor growth [37,38] whereas in others tumor growth has been
inhibited [38,39]. In chronic B lymphocytic leukemia (B-CLL)
models IL-13 has been shown to block apoptosis of tumor cells
[40,41].
In this study we demonstrate that vigorous MCPyV-specific Th
cell responses are readily detectable in constitutionally healthy
adults.
Results
Proliferation responses among MCPyV-seropositive and
seronegative subjects
We determined MCPyV-specific T-cell proliferation in 15
MCPyV-seropositive and 15 seronegative subjects. Virus-specific
proliferation responses of the MCPyV-seropositive subjects were
much stronger than those of the seronegative subjects, both at
0.25 mg/ml and 2.5 mg/ml concentrations of antigen (Tables 1
and 2 and Fig. S1).
The proliferation responses became more vigorous when the
MCPyV-antigen concentration was elevated from 0.25 mg/ml to
2.5 mg/ml. The increase in mean response was ,2 fold among the
seropositive subjects, and even higher, ,5 fold among the
seronegative controls (Tables 1 and 2). These increases were
statistically significant both among the seropositive (P = 0.011) and
seronegative subjects (P = 0.002).
Six seropositive and none of the seronegative subjects were
responders (having DCPM.5000) with the lower 0.25 mg/ml
antigen concentration (P = 0.017). With the higher 2.5 mg/ml
concentration, the corresponding numbers were 12 and three
among the seropositive and seronegative subjects, respectively
(P = 0.001) (data not shown). With the control antigens HBoV
(Table 3) and Candida albicans (Table 4) no statistically significant
differences in proliferation were found. With the responder criteria
the control-antigen specific responses were statistically identical
among the MCPyV-seropositive and seronegative subjects, P = 1.0
with both antigens (data not shown).
IFN-c, IL-10 and IL-13 responses among MCPyV-
seropositive and seronegative subjects
MCPyV-specific IFN-c, IL-10 and IL-13 responses were readily
detectable even with the lower 0.25 mg/ml antigen concentration
among the seropositive subjects, and they were significantly
stronger than the corresponding responses among the seronegative
subjects (Table 1).
With the 2.5 mg/ml MCPyV antigen concentration the average
cytokine responses were higher than with the 0.25 mg/ml
concentration (Tables 1 and 2), and the differences were
statistically significant with all the cytokines, both among the
seropositive (P#0.011) and seronegative (P#0.018) subjects.
Also with the higher MCPyV antigen concentration the
cytokine responses were stronger among the seropositive subjects
than among the seronegative ones. The difference was particularly
evident with IFN-c, and also significant with IL-10 and IL-13
(Table 2 and Fig. S1).
With the control antigens the cytokine responses were very
similar among the MCPyV seropositive and seronegative subjects.
The P-values with the HBoV and Candida albicans antigens were
$0.305 and $0.285, respectively (Tables 3 and 4).
As seen in Tables 1 and 2, IFN-c was the dominant MCPyV-
associated cytokine. Also at individual level, a response pattern of
IFN-c.IL-10 and IFN-c.IL-13 was often detected with both
antigen concentrations (P#0.014). Among the seronegative
subjects this pattern was not borne at MCPyV VLP concentration
of 0.25 mg/ml (P$0.444), whereas at the higher concentration also
the seronegative subjects tended to show higher responses with
IFN-c than with IL-10 (P = 0.069) or with IL-13 (P = 0.047).
With the positive control antigen HBoV (Table 3) IFN-c
responses were also higher than the corresponding IL-10 or IL-13
Table 1. Comparison of MCPyV-specific proliferation and
cytokine responses among 15 MCPyV seropositive and 215
seronegative subjects at 0.25 mg/ml antigen concentration.
MCPyV
serostatus DCPMa±SD
IFN-c pg/
mL±SD
IL-10 pg/
mL±SD
IL-13 pg/
mL±SD
Positive 587865959 159.86234.0 23.3630.5 23.5628.2
Negative 5346660 6.568.40 4.5064.80 4.065.40
P ,0.0001 0.006 0.026 0.021
aD CPM: antigen-specific CPM- background.
doi:10.1371/journal.pone.0025751.t001
Table 2. Comparison of MCPyV-specific proliferation
and cytokine responses among MCPyV seropositive and
–seronegative subjects at 2.5 mg/ml antigen concentration.
MCPyV
serostatus DCPMa IFN-c pg/mL IL-10 pg/mL IL-13 pg/mL
Positive 956267419 280.76197.6 51.2656.0 56.5654.9
Negative 308663918 51.8660.6 22.7621.8 20.5626.4
P 0.001 ,0.0001 0.041 0.019
aD CPM: antigen-specific CPM- background.
doi:10.1371/journal.pone.0025751.t002
Table 3. Comparison of HBoV-specific proliferation and
cytokine responses among MCPyV seropositive and
–seronegative subjects at 2.5 mg/ml antigen concentration.
MCPyV
serostatus DCPMa IFN-c pg/mL IL-10 pg/mL IL-13 pg/mL
Positive 670467937 121.36154.4 15.9641.8 74.46118.1
Negative 6884611106 127.86214.0 10.9621.5 45.1671.2
P 0.174 0.345 0.624 0.305
aD CPM: antigen-specific CPM- background.
doi:10.1371/journal.pone.0025751.t003
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responses, both among the seropositive (P#0.030) and seronega-
tive subjects (P#0.026).
Finally, we compared the same MCPyV-seropositive subjects’
MCPyV-derived IFN-c responses with the same subjects’ HBoV-
derived IFN-c responses. Significantly stronger IFN-c responses
were detected with MCPyV-antigen than with HBoV antigen
(P = 0.016) (data not shown).
Identification of the proliferating and cytokine secreting
cells
To identify the proliferating and cytokine secreting cell
populations, the PBMC were depleted either of CD4+ or CD8+
T cells by using monoclonal antibodies (MAbs) attached to
magnetic beads. Seropositive subjects P1 to P4 and a seronegative
subject N1 who had constantly shown strong responses with
MCPyV were studied. MCPyV-specific proliferation, IFN-c, IL-
10 and IL-13 secretion was readily detectable after depletion of
CD8+ T cells, whereas the removal of CD4+ T cells strongly
reduced the responses among all the subjects (Fig. 1).
HLA restriction of cytokines and proliferating cells
HLA class restriction of the cytokine and proliferation responses
were studied with a class II-specific MAb (which blocks antigen
presentation) and with an isotype-matched control MAb. Sero-
positive subjects (P1, P2, P3 and P5) together with a seronegative
subject (N1) were studied. With the isotype control MAb
proliferation and cytokine responses were readily detectable,
whereas they were invariably reduced with the HLA class II-
specific MAb (Fig. 2).
Discussion
A significant proportion of human population has encountered
MCPyV. Because neutralizing MCPyV antibodies occur in high
titers in patients with MCC [18], it is likely that infection
surveillance is not completely mediated by humoral immunity.
Instead, cell mediated immune mechanisms may play a central
role, yet they have not been explored so far. The present study is
the first to report on cell-mediated immunity against MCPyV. The
Table 4. Comparison of Candida albicans-specific
proliferation and cytokine responses among MCPyV
seropositive and –seronegative subjects at 2.5 mg/ml antigen
concentration.
MCPyV
serostatus DCPMa IFN-c pg/mL IL-10 pg/mL IL-13 pg/mL
Positive 42728632744 1179.861367.8 481.36387.9 225.26186.0
Negative 30379637614 1174.261318.1 661.46456,3 183.76230.6
P 0.106 0.486 0.285 0.305
aD CPM: antigen-specific CPM- background.
doi:10.1371/journal.pone.0025751.t004
Figure 1. MCPyV VP1–specific T cell responses of MCPyV seropositive individuals after T cell subset depletion. PBMC of four MCPyV
seropositive (P1 to P4) and one seronegative subject with strong MCPyV-specific CMI (N1) were depleted of either CD4+ or CD8+ T cells and
stimulated with MCPyV VP1-VLPs (2.5 mg/ml). Proliferation (panel A) and cytokine (IFN-c, IL-13 and IL-10) responses (panel B, C, D) were studied by
thymidine incorporation and ELISA, respectively.
doi:10.1371/journal.pone.0025751.g001
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responses were regarded to be highly specific for MCPyV, as the
studies were carried out by using highly purified (Fig. 3) VLPs. T-
cell subset depletion and HLA class II blocking showed that the
main sources of MCPyV-specific proliferation and cytokine
responses were CD4+ Th-cells, not the cells of innate immunity,
even in a MCPyV seronegative subject (N1) showing strong
cellular responses to MCPyV.
The concentration of the MCPyV-antigen used in the assay had
a significant importance. With the lower concentration a
‘‘classical’’ response pattern was observed: Th-cell proliferation
and cytokine responses were largely confined within the
seropositive subjects. However, with the higher concentration,
MCPyV-specific responses were detectable also among some
seronegative subjects. This type of responders have been
previously denoted as ‘‘immune seronegative’’ subjects in a herpes
simplex virus model [42,43]. With both antigen concentrations the
seropositive subjects nevertheless had significantly stronger
MCPyV-specific Th-cell responses than the seronegative subjects
had, whereas Th-cell responses against the control antigens HBoV
and Candida albicans were statistically similar in the two groups.
The presence of MCPyV- seronegative responders suggests that B-
cell immunity against MCPyV is not always persistent, or that a
degree of cross-reactivity in the VP1 Th-cell epitopes may exist
between MCPyV and some hitherto-unidentified virus. VP1
proteins of other polyomaviruses are possible candidates. For
instance, the VP1 protein of a recently discovered trichodysplasia
spinulosa-associated polyomavirus (TSPyV) has as high as 50.6%
amino-acid similarity with that of MCPyV [44]. Alternatively,
some MCPyV strains might be of aberrant B-cell antigenicity. One
such MCPyV strain, termed ‘‘350’’, having critical double
mutations at VP1 positions 288 and 316, has been described to
date [45]. VP1 of strain ‘‘350’’ is not recognized by sera strongly
reactive with VP1s of MCPyV strains lacking these mutations [45].
Furthermore, it remains possible that the MCPyV-reactive Th
cells have been originally primed by pathogens possessing largely
different T cell epitopes. This is because a very high level of
crossreactivity is an essential feature of the T-cell receptor [46–49].
We found that MCPyV specific Th-cells secrete the Th2-like
cytokine IL-13, the regulatory-like cytokine IL-10 and the Th1-like
cytokine IFN-c. MCPyV-specific IL-10 may have importance in
regulation of humoral immunity (Note S1). IFN-c was the most
readily detectable cytokine with MCPyV, and the responses were
significantly stronger than the corresponding responses with the
HBoV positive-control antigen, highlighting the strength of this
response. This is the main finding of our study, due to the tumor-
suppressing and antiviral functions of this cytokine. Of note,
cellular infiltration and cytokine mRNA (including IFN-c) have
been studied in MCC biopsies. Arany and Tyring found lacking of
Figure 2. Effect of HLA class II-specific monoclonal antibodies (MAbs) on MCPyV-VP1 specific proliferation and cytokine responses.
PBMC from four MCPyV seropositive subjects (P1 to P3 and P5) and from a seronegative subject (N1) were incubated either with a HLA class II-specific
blocking MAb or with an isotype-matched control MAb. The effect of these MAbs on MCPyV-specific (2.5 mg/ml) proliferation (panel A) and cytokine
(panels B, C and D) responses are shown. Subjects P1 to P3 and N1 are same than in Figure 1.
doi:10.1371/journal.pone.0025751.g002
Th-Cell Immunity against Merkel Cell Polyomavirus
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25751
IFN-c responses in MCC biopsies [50], whereas Kelly et al found
an association between favorable prognosis and the presence of
elevated expression of IFN-c mRNA [51]. It should be noted that
in these studies the antigen specificity of tumor infiltrating
lymphocytes was not determined.
Taken together, the antigen-specific Th-cell responses of
healthy individuals in the present study along with studies showing
a lack of Th-cell responses on a general level in patients with MCC
suggest a central role for CMI in infection surveillance of MCPyV.
The imperative next step is to study MCPyV-related diseases such
as MCC or CLL for antigen-specific CMI to get further evidence
of the pathogenic importance of MCPyV-specific Th immunity.
Materials and Methods
Study groups
Altogether randomly selected 30 asymptomatic subjects (age
range 25–58 years) were studied: 15 were seropositive and 15
seronegative for MCPyV. This study protocol followed the human
experimentation guidelines of the US Department of Health and
Human Services in the conduct of clinical research and was
approved by the ethics committee of the Department of Medicine
in Helsinki University Central Hospital. Written informed consent
was obtained from all volunteers.
Antigens for proliferation and cytokine assays
MCPyV VP1 and HBoV VP2 capsids were expressed with
recombinant baculoviruses in Sf9 cells and purified by CsCl
gradient ultracentrifugation [52–54]. After extensive dialysis the
protein was concentrated and purified further by using 50 KDa
MWCO centrifugal filters (Amicon Ultra, Millipore, Billerica,
MA). The antigens were further characterized by silver staining
(SilverXpress, Invitrogen, Carlsbad, CA, USA) (Fig. 3 A) and dot
blotting (Fig. 3 B) with MCVPy seropositive human sera as
described earlier [52,53]. The purity for MCPyV protein was
.90% by densitometry (Gel Doc 2000 Gel Documentation
systems with Quantity One Quantitation Software, Bio-Rad).
Electron microscopy with negative staining showed virus-like
particles (Fig. 3 C). As a second control antigen, we used in-house
prepared and heat inactivated Candida albicans. Endotoxin in the
antigen preparations was measured by the Limulus amebocyte
lysate assay (QCL-1000; Cambrex Biosciences, Walkersville, MD,
USA), and it was less than 2 EU/mg with MCPyV and HBoV
antigens.
Antibody assay
We measured MCPyV and HBoV IgG in plasma by EIA,
employing as antigen virus-like particles [52,54].
Isolation of PBMC
Blood was drawn to mononuclear cell separation tubes
(Vacutainer CPT, Becton Dickinson, Franklin Lakes, NJ, USA).
The tubes were centrifuged at 15006g for 30 minutes and washed
two times with PBS. PBMC were separated within 2 hrs of blood
sampling followed by counting [55].
Lymphocyte culture
For lymphocyte culture, isolated PBMC were resuspended in
RPMI-1640 (Sigma, St Louis, MO, USA) containing 20 mM
HEPES, 2 mM L-glutamine, streptomycin (100 mg/ml), penicillin
(100 U/ml), 50 mM 2-mercaptoethanol and 10% human AB
serum (Cambrex Biosciences, USA) and were cultured with the
antigens [55]. MCPyV VLP were used at 0.25 mg/ml and 2.5 mg/
ml and the HBoV VLP and Candida albicans control antigens at
2.5 mg/ml.
Proliferation assay
Counted PBMC and antigens in triplicate were placed in 96
well U-bottom plates (Coster, Corning Inc., Corning, NY, USA).
Cells (200,000/well) were cultured for 6 days (37uC; 5% CO2) and
pulsed for the last 16 hours with 1 mCi of tritiated thymidine
(specific activity 50 Ci/mmol; Nycomed Amersham, Buckingham-
shire, UK). Thymidine incorporation was measured in a liquid
scintillation counter (Microbeta, Wallac,Turku, Finland). The data
were expressed as counts per minute (D cpm): D cpm=mean cpm
(test antigen)2mean cpm (media) [53,55].
Figure 3. Characterization of MCPyV VP1 antigens. Silver staining of capsid protein (panel A) in 10% SDS PAGE. Lane 1: molecular weight
markers, lane 2: MCPyV VP1 capsid antigen. Dot blotting (panel B) for MCPyV antigen, studied with MCPyV-IgG positive (I) and negative (II) sera.
Electron microscopy of sterile MCPyV particles (panel C) purified by caesium chloride density gradient ultracentrifugation, with 200 nm scale bar
shown.
doi:10.1371/journal.pone.0025751.g003
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Cytokine assays
PBMC culture supernatants were harvested after 3 days for
IFN-c and after 5 days for IL-10 and IL-13, and were stored at
220uC. Cytokine production in the supernatants was analysed by
IFN-c, IL-10 (Pharmingen, San Diego, CA, USA) and IL-13
(Invitrogen corporation CA, USA) kits, according to the
manufacturers’ instructions. Background (media) cytokine produc-
tion was subtracted from total to yield antigen specific cytokine
production. The detection limits for IFN-c, IL-10 and IL-13 were
5, 8 and 6 pg/ml, respectively.
Depletion of CD4+ or CD8+ cells
PBMC were depleted of CD4+ or CD8+ T cells by using
magnetic beads coated with CD4- or CD8-specific monoclonal
antibodies (Invitrogen Dynal AS, Oslo, Norway), according to the
manufacturer’s instructions. Then, 200,000 pure CD4+ or CD8+
depleted cells were cultured with the antigens as described [55].
Antibody blocking assays
Class restriction of the T-cell responses was further studied by
HLA class II-specific MAbs (HLA-DR, DP, DQ) (IgG2a, clone
Tu39; BD PharMingen), or isotype control MAb (IgG2a, clone
G155- 178; BD PharMingen). These antibodies were used at
5 mg/ml, according to the manufacturer’s instructions.
Statistical methods
Responses among MCPyV seropositive and seronegative
subjects were compared by using the Mann-Whitney U test.
Paired responses were evaluated by using the Wilcoxon Signed
Rank test. The distribution of responders having D cpm.5000
[42,43] against each antigen was studied using Fisher’s Exact test.
P values,0.05 were considered significant. All analyses were done
with a SPSS statistical program version 15.0.
Supporting Information
Figure S1 Cytokine and proliferation responses in the
15 MCPyV seropositve (A) and 15 seronegative (B)
subjects with the 2.5 mg/ml MCPyV antigen (&) and
media (%).
(PDF)
Figure S2 Cytokine responses versus mg/ml MCPyV
IgG titers in the 15 seropositive subjects. Responses from a
seropositive subject with strong MCPyV-specific cytokine respons-
es but low titers of MCPyV IgG are shown with an open triangle
(D).
(PDF)
Note S1 Antibody versus cytokine responses in 15
MCPyV seropositive subjects.
(PDF)
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